Sentence examples for molecular screening with from inspiring English sources

Cheng, Z. et al. Capture and ligation probe-PCR (CLIP-PCR) for molecular screening, with application to active malaria surveillance for elimination.

The overall rate of Bartonella-positive fleas by molecular screening with real-time PCR was 7.4% (6/81): 6 fleas from the cat (6/13) and none from a dog (0/68).

One individual per island per species was selected for a first molecular screening with five DNA regions [i.e. ITS and four cpDNA (matK, psbA-trnH, rbcL, trnL-F)] in order to ascertain which regions are variable within each species.

As a result, most ongoing molecular screening programs with genotyping or NGS use stored formalin-fixed and paraffin-embedded (FFPE) samples for testing with a targeted cancer or disease site-specific panel, including hotspots, amplicons, or entire exons within genes where mutations are known to occur and may be relevant to treatment selection.

Sequist and colleagues [ 40] published their experience at Massachusetts General Hospital with molecular screening of 552 patients with NSCLC by using the multiplex PCR-based SNaPshot assays, which detect around 50 mutations from 14 genes, and fluorescence in situ hybridization (FISH) for ALK translocations.

This seems to correspond to the purpose of molecular screening and agree with Lemmon and Gardner who reported that a signature with high sensitivity but perhaps low specificity may be preferred in the clinical laboratory [ 34].

For several reasons, non-endoscopic molecular screening of BE with accurate biomarkers is feasible and could become a novel, effective approach to control the rapidly increasing rates of EAC.

This empirical work speaks to the growing diseasification of risk that molecular screening technologies facilitate, with risk 'treated' in much the same way as disease itself, through medical means such as medication, behaviour modification and surgical intervention (Armstrong, 1995; Sachs, 1995; Clarke et al, 2003, 2010; Aronowitz, 2009; Sulik, 2011; Gillespie, 2012).

This paradigm is challenged by the need to perform widespread molecular screening in certified laboratories, with results available to clinicians within reasonable timeframe.

Results of molecular screening tests were congruent with the typing results.

Thus, AURORA will serve as a molecular screening filter, guiding patients with metastatic breast cancer to innovative clinical trials and accelerating the clinical development of promising targeted agents within the appropriate molecular niches of the disease.